GlassScriptPhysician profile
Jimmy W Dailey
NPI 1073598199
$1,769.72
in general payments reported to CMS, 2019-2025
21 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $193 · 2021: $274 · 2022: $318 · 2023: $416 · 2024: $257 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $433.81 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $367.34 | 2021-2023 | |
| Novo Nordisk INC | $304.97 | 2019-2024 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $85.26 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $83.73 | 2021-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $71.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.95 | 2019 | |
| Glaxosmithkline, LLC. | $51.39 | 2024-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $46.69 | 2023-2025 | Veozah |
| Pfizer INC. | $44.07 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.67 | 2023-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $27.60 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $27.25 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $26.09 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $22.76 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $21.84 | 2024 | Freestyle Libre 3 |
| Abbvie INC. | $19.02 | 2023 | Ubrelvy |
| Philips North America LLC | $14.70 | 2025 | Mcot |
| Teva Pharmaceuticals USA, INC. | $12.99 | 2019 | |
| Amarin Pharma, INC. | $12.37 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.